Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense(R) in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines CAESAREA, ...
CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...
The MarketWatch News Department was not involved in the creation of this content. Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse ...
"We had a very successful participation at CIRSE this year, as ProSense® offers what we believe is the most advanced clinically proven LN2 cryoablation system to the growing number of interventional ...
(MENAFN- Investor Ideas) ) a go-to platform for big investing ideas, including biotech and medical tech stocks issues a news and trading alert for IceCure Medical Ltd. (NASDAQ: ICCM ), IceCure Medical ...
(MENAFN- Investor Ideas) ) a go-to platform for big investing ideas, including biotech stocks, covers IceCure Medical (Nasdaq: ICCM ) reporting 70% growth in its active U.S. commercial install base ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Icecure Medical ( (ICCM)) ...
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg View original content:https://www.prnewswire.com/news-releases/icecure-medical-reports-2024 ...
IceCure Medical's ProSense (R) Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results